Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant (2016) 0.75

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet (2000) 4.67

Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis (2002) 4.65

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood (1996) 3.12

How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood (2010) 2.82

Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev (2009) 2.75

Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant (2009) 2.57

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood (2003) 2.05

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant (2003) 2.03

The EBMT activity survey: 1990-2010. Bone Marrow Transplant (2012) 1.96

High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis (2002) 1.93

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood (2001) 1.93

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.77

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol (2008) 1.49

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood (2000) 1.46

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood (1986) 1.40

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood (2003) 1.39

Feeling manipulated: cytomegalovirus immune manipulation. Virol J (2009) 1.19

Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol (2008) 1.13

Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol (2010) 1.12

Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol (2004) 1.11

Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program (2011) 1.01

Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant (2003) 1.00

Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol (2004) 0.95

Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant (2002) 0.90

Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol (2011) 0.90

Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis (2002) 0.87

Antiviral therapy of CMV disease in children. Adv Exp Med Biol (2011) 0.85

Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes (2008) 0.83

Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant (1996) 0.82

A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant (2000) 0.82

Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol Oncol (2008) 0.80

Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplant (2009) 0.79

Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant (1996) 0.78

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant (2015) 1.22

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant (2016) 0.89

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant (2017) 0.75